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Abstract
Myeloid-derived suppressor cells (MDSC) are induced under diverse pathologic conditions, including neoplasia, and
suppress innate and adaptive immunity. While the mechanisms by which MDSC mediate immunosuppression are well-
characterized, details on how they develop remain less understood. This is complicated further by the fact that MDSC
comprise multiple myeloid cell types, namely monocytes and granulocytes, reflecting diverse stages of differentiation and
the proportion of these subpopulations vary among different neoplastic models. Thus, it is thought that the type and
quantities of inflammatory mediators generated during neoplasia dictate the composition of the resultant MDSC response.
Although much interest has been devoted to monocytic MDSC biology, a fundamental gap remains in our understanding of
the derivation of granulocytic MDSC. In settings of heightened granulocytic MDSC responses, we hypothesized that
inappropriate production of G-CSF is a key initiator of granulocytic MDSC accumulation. We observed abundant amounts of
G-CSF in vivo, which correlated with robust granulocytic MDSC responses in multiple tumor models. Using G-CSF loss- and
gain-of-function approaches, we demonstrated for the first time that: 1) abrogating G-CSF production significantly
diminished granulocytic MDSC accumulation and tumor growth; 2) ectopically over-expressing G-CSF in G-CSF-negative
tumors significantly augmented granulocytic MDSC accumulation and tumor growth; and 3) treatment of naı ¨ve healthy
mice with recombinant G-CSF protein elicited granulocytic-like MDSC remarkably similar to those induced under tumor-
bearing conditions. Collectively, we demonstrated that tumor-derived G-CSF enhances tumor growth through granulocytic
MDSC-dependent mechanisms. These findings provide us with novel insights into MDSC subset development and
potentially new biomarkers or targets for cancer therapy.
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Introduction
Myeloid-derived suppressor cells (MDSC) constitute heteroge-
neous populations of monocytic and granulocytic-like cells
reflecting various stages of differentiation that are well-regarded
to play integral roles in immune suppression during diverse
pathologic conditions, notably chronic inflammation, infection,
trauma, graft-versus-host disease and neoplasia [1,2,3,4,5,6,7,8].
Such regulatory myeloid populations accumulate in the bone
marrow, blood, peripheral lymphoid tissues and sites of disease
activity, such as cancer. In fact, MDSC have been identified in
various human hematologic and non-hematologic malignancies, as
well as in both implantable and autochthonous animal tumor
models indicating that their existence represents a key component
of the neoplastic process. The notion that MDSC constitute a
significant barrier to effective anti-pathogen immunity has led to a
comprehensive understanding of their mechanisms of immune
suppression [1,2,3,4,5,6,7,8,9,10,11,12].
Despite the fact that much attention has been dedicated to
unraveling mechanisms by which MDSC mediate immune
suppression, a larger gap remains in our understanding of the
mechanisms that initiate their development. Understanding how
they appear is also critical to the design of new therapeutic
strategies that impede MDSC involvement in order to potentiate
anti-pathogen immunity. In the case of neoplasia, it is generally
thought that tumor-derived factors (TDF) govern diverse facets of
MDSC biology, including their mobilization, recruitment and
activation [1,3,4,5,6,8,13,14,15]. In mouse models MDSC are
broadly defined as CD11b
+Gr-1
+ cells [1,5,16,17]. More recently,
MDSC have been divided into monocytic and granulocytic
subsets, reflecting differential expression of the Ly6C and Ly6G
epitopes. Monocytic MDSC are characterized as CD11b
+Ly6-
C
high Ly6G
2 or CD11b
+Gr-1
low cells whereas granulocytic
MDSC are defined as CD11b
+Ly6C
low Ly6G
+ cells or
CD11b
+Gr-1
high [6,16,17]. Interestingly, recent studies reported
that in the vast majority of tumor models, as well as in cancer
patients, granulocytic MDSC are a predominant MDSC subset
[1,17,18,19,20,21]. In fact, 70–80% of the tumor-induced MDSC
response may consist of granulocytic-like cells compared to 20–
30% of the cells reflecting the monocytic lineage [9,17,18]. It has
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27690also been reported that both subsets are equally suppressive on a
per cell basis [17].
Although much interest has been dedicated to monocytic
MDSC biology [3,4,5,6,13,14,22], less is understood about the
origin of granulocytic MDSC. Therefore, in this study we focused
on the mechanistic basis of granulocytic MDSC accumulation and
its relevance to tumor growth. Given that the MDSC response is a
consequence of altered myelopoiesis [1,3,4,5,6,8], we reasoned
that, when aberrantly expressed, tumor-derived granulocyte-
colony stimulating factor (G-CSF) represents a key inflammatory
component that facilitates granulocytic MDSC accumulation.
Ordinarily, endogenous G-CSF regulates granulopoiesis and has
an integral role in neutrophil mobilization in response to various
insults [23]. Exogenous G-CSF is also important to overcome
neutropenia caused by various anti-neoplastic treatments [23].
However, G-CSF exposure paradoxically can also elicit adverse
effects, and inhibit innate and adaptive immunity [24,25]; yet, the
precise mechanisms by which G-CSF does so remain incompletely
understood. Moreover, the idea that G-CSF may not always be
beneficial to the host is supported by the findings that G-CSF is
aberrantly expressed by diverse human tumors, including head
and neck, cervical, ovarian, pancreatic, bladder and leukemia
[26,27,28,29,30,31].
Indeed, G-CSF production has also been shown to correlate
with aberrant granulocytic or MDSC-like responses in several
mouse tumor models [32,33,34]; however, the mechanistic link
between G-CSF and granulocytic MDSC generation has not been
determined. Moreover, the correlation between G-CSF and
MDSC accumulation has largely focused on the global
(CD11b
+Gr-1
+) MDSC response [35,36], making it difficult to
distinguish and conclude the impact of G-CSF on the monocytic
vs. granulocytic MDSC subsets. Thus, this study focused on three
fundamental questions: 1) Does tumor-derived G-CSF drive
granulocytic MDSC generation in vivo? 2) Is the granulocytic
MDSC response pro-tumorigenic in vivo? and 3) Does recombinant
G-CSF administration elicit a myeloid response phenotypically,
functionally and molecularly similar to that of G-CSF-producing
tumors? The latter question not only addresses the mechanistic
link between G-CSF and granulocytic MDSC development in vivo,
but also the potential implications of aphysiologic G-CSF levels in
non-neoplastic disease or clinical settings.
Results
G-CSF is Produced at High Levels by Several Mouse
Tumor Models
To test our hypothesis, we made use of two implantable
orthotopic mouse models of mammary cancer that are proficient
at MDSC generation, termed 4T1 and AT-3. 4T1 is a well-
characterized mammary tumor model [37] that induces a rapid
accumulation of systemic and intratumoral MDSC, broadly
defined by their CD11b
+Gr-1
+ expression [1,5,17]. The AT-3
mammary tumor cell line, recently generated in our laboratory
[38], was established from a primary mammary carcinoma of the
MMTV-PyMT transgenic mouse model [39], henceforth termed
MTAG mice. CD11b
+Gr-1
+ MDSC responses are observed under
autochthonous (i.e., MTAG) and implantable (i.e., AT-3) tumor
settings [38].
We first screened tissue culture supernatants of 4T1 cells for
cytokines and chemokines commonly associated with myelopoiesis
and MDSC biology [1,3,5,6,8,13,14,38]. We found extremely
high levels of G-CSF production, whereas only marginal amounts
of all other factors tested were detectable (Fig. 1A). Similarly, AT-3
cells produced high levels of G-CSF (Fig. 1B). Analysis of two
additional mammary tumor cell lines, DA-3 and EMT6, yielded
substantially high levels of G-CSF (Fig. S1). In contrast to these
four cell lines, G-CSF production was not detectable in the CMS4
sarcoma cell line (Fig. 1B). It is worth noting that mice implanted
with sarcomas generally display minimal MDSC burden [17].
We then examined G-CSF levels in the sera of 4T1 and AT-3
tumor-bearing mice (Fig. 1C). High levels of G-CSF were
observed in both groups of tumor-bearing mice, whereas nominal
amounts were detectable in the non-tumor-bearing control mice.
As an additional control, mice were injected with recombinant G-
CSF protein (Fig. 1C). Analysis of G-CSF protein revealed copious
amounts in the blood reflecting a concentration range seen under
tumor-bearing conditions. Lastly, sera G-CSF levels were
measured in separate groups of MTAG mice at discrete stages
of autochthonous tumor growth: no palpable tumors, minimal
tumor burden (i.e., ,200 mm
3) and extensive tumor burden (i.e.,
.1500 mm
3). Not surprisingly, G-CSF levels increased with
increasing tumor burden. In contrast, little-to-no G-CSF was
observed in the non-tumor-bearing controls (Fig. 1D). G-CSF
levels in mice with large tumor burdens paralleled the high levels
found in the implantable models. These data indicate that G-CSF
is produced at high levels in multiple tumor models, and represents
a potentially critical player for altered myelopoiesis and granulo-
cytic MDSC generation. These studies also extend observations
made elsewhere [32,33,34] regarding correlations between tumor
growth and G-CSF production.
Phenotypic and Functional Properties of CD11b
+Gr-1
+
cells from G-CSF-Treated Hosts
To gain insights into the role of G-CSF as a potential mediator
of granulocytic MDSC development, we compared the MDSC
response generated in tumor-bearing mice to mice treated with
recombinant mouse G-CSF protein (Fig. 2A). In control mice, the
percentage of CD11b
+Gr-1
+ myeloid cells was ,7%. In contrast,
treatment of mice with G-CSF protein caused significant
splenomegaly, resulting from a massive expansion of CD11b
+Gr-
1
+ myeloid cells (Fig. 2A) with a corresponding decrease in the
percentage of cells within the lymphoid compartment (Fig. S2
panel A). The accumulation of such myeloid cells was comparable
to the CD11b
+Gr-1
+ myeloid response during AT-3 or 4T1 tumor
growth (Fig. 2A).
While the co-expression of CD11b and Gr-1 markers
encompass the ‘global’ MDSC population, the Gr-1 epitopes,
Ly6C and Ly6G are used to delineate monocytic and granulocytic
MDSC subsets [16,17]. Using these additional phenotypic
markers, splenocytes from G-CSF-treated mice displayed a
prominent expansion of granulocytic-like cells (81.4% granulocytic
vs. 8.2% monocytic) compared to control mice (23.5% granulo-
cytic vs. 16.9% monocytic) (Fig. 2B). Indeed, the phenotypic
pattern observed in G-CSF-treated mice paralleled that seen in
AT-3 and 4T1 tumor-bearing mice (Fig. 2B). Morphologic
analysis confirmed their monocytic and granulocytic lineages
(Fig. S2 panel B).
Next, we examined and compared the suppressive capacity of
splenic CD11b
+Gr-1
+ cells from control, G-CSF-treated and AT-3
tumor-bearing mice, based on inhibition of polyclonal or allo-
specific T cell proliferation as readouts of suppressive behavior.
Similar to what we observed previously using CD11b
+Gr-1
+ cells
from 4T1 tumor-bearing mice [38], cells from G-CSF-treated
mice also exerted significant suppression of polyclonal T cell
proliferation (Fig. 2C). Moreover, we observed that CD11b
+Gr-1
+
cells from G-CSF-treated and AT-3 tumor-bearing mice, but not
control mice significantly suppressed allo-specific T cell prolifer-
ation (Fig. 2D). Overall, the CD11b
+Gr-1
+ responses generated by
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in terms of phenotype, morphology and functional suppression.
CD11b
+Gr-1
high Cells from G-CSF-Treated and Tumor-
Bearing Hosts are Also Comparable at a Molecular Level
Global gene expression studies were performed to determine
whether the granulocytic-like MDSC populations from G-CSF
treated mice resembled those of tumor-bearing (TB) mice more so
than those of the non-tumor-bearing control (i.e., WT) at a
molecular level. To that end, splenic CD11b
+Gr-1
high cell
populations from WT, 4T1-TB or G-CSF-treated BALB/c mice
(as in Fig. 2) were purified in two independent experiments by flow
cytometry (.98% purity) and subjected to whole genome
expression profiling using Illumina microarrays (see Materials
and Methods). Differential expression analysis of microarray data
revealed that the gene expression patterns of cells from G-CSF-
treated mice resembled those of 4T1-TB hosts more than of the
WT group (Fig. 3). Specifically, we identified 932 and 734 genes
showing significant expression changes (i.e., .2-fold change,
P,0.01) in 4T1-TB vs. WT comparison and G-CSF vs. WT
comparison respectively, and only 22 genes were differentially
expressed between 4T1-TB and G-CSF using the same signifi-
cance criteria (Fig. 3A). Hierarchical clustering based on identified
differentially expressed genes showed that G-CSF and 4T1-TB
samples were clustered into a group separated from that of the WT
samples (Fig. 3B). Overall, based on microarray gene expression
profiling analysis, these data indicate that G-CSF administration
can recapitulate a granulocytic-like MDSC phenotype highly
comparable to that of tumor-bearing mice.
G-CSF Blockade Diminishes Tumor Growth
To test the hypothesis that G-CSF production is causally linked
to MDSC generation and/or tumor growth, we sought to inhibit
G-CSF in tumor-bearing mice using two different approaches.
Figure 1. G-CSF production by various mouse tumor models. (A) Cell-free supernatants from 4T1 tumor cells were analyzed for the indicated
TDF by ELISA. Data are reported as pg/ml/10
6 cells/24 hr, and reflect the mean 6 SEM of 3 or more separate experiments for each cytokine tested. (B)
G-CSF levels were then analyzed in a similar fashion for the AT-3 and CMS4 tumor cell lines. Data are reported as the mean 6 SEM of triplicate
determinations, and are representative of 3 separate experiments. (C) Sera G-CSF levels determined from nontumor-bearing mice (n=10), mice
treated with recombinant G-CSF protein (10 mg daily for 5 consecutive days) (n=8) or mice bearing 4T1 cells (n=9) or AT-3 tumor cells pooled from
two separate experiments (n=9; overall tumor volume #2cm
3). Each data point represents the results from an individual mouse. G-CSF levels of all
experimental groups were significantly different compared to the nontumor-bearing control mice (P,0.0001). (D) Sera were collected from MTAG
mice at the tumor burdens indicated, and analyzed for G-CSF levels. Mice bearing small tumor burdens showed significantly elevated (P,0.04) levels
of G-CSF compared to MTAG mice without measurable tumor growth. G-CSF levels were more pronounced at larger tumor burdens (P,0.02,
compared to ‘no tumor’ group). Each data point represents a single mouse.
doi:10.1371/journal.pone.0027690.g001
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primary tumor growth compared to mice treated with the isotype
control Ab (Fig. 4A), suggesting an important pro-tumorigenic role
of G-CSF during AT-3 tumor growth. It is unlikely that G-CSF
acts in an autocrine fashion, as AT-3 (as well as 4T1) tumor cells
do not express detectable cell surface G-CSF receptor.
Second, we made use of a loss-of-function approach, whereby G-
CSF expression was down-regulated in AT-3 cells via RNA
interference. Individual stable cell lines were generated using
different short-hairpin (shRNA) sequences delivered via retroviral-
based methods. G-CSF knockdown, relative to the non-silencing
(scrambled sequence) control, was strongly observed with all
constructs, as measured by RT-PCR (Fig. 4B). In contrast, genes
associated with other aspects of tumor biology, such as PyMT
(MTAG tumor-specific), COX-2, VEGF-A and VEGF-C remained
unaffected compared to the control (Fig. 4B). G-CSF protein levels
in tumor cell supernatants were also significantly reduced (Fig. 4C).
Since all three constructs appeared to be effective in silencing G-
CSF expression, we arbitrarily selected cells transduced with
construct 1 for further studies. Using these cells, termed AT-3
shRNA 1, we explored the impact of G-CSF loss on tumor growth
and MDSC accumulation in vivo. To that end, syngeneic female B6
m i c ew e r ei m p l a n t e do r t h o t o p i c a l l yw i t hA T - 3s h R N A1c e l l so rt h e
control tumor cells. Consistent with our observations using Ab-based
G-CSF blockade (Fig. 4A), AT-3 shRNA 1 tumor cells grew
significantly slower than control tumor cells at multiple time points
(Fig. 4D). In contrast, both cell lines proliferated similarly in vitro (Fig.
S3 panel A), suggesting that in vivo interactions influenced tumor
growth patterns. To verify that differences in tumor growth patterns
correlated with differences in G-CSF levels, sera from both groups of
Figure 2. Recombinant G-CSF promotes immunosuppressive myeloid cells. (A) Phenotypic analysis for co-expression of CD11b and Gr-1
markers on unfractionated splenocytes from mice injected with recombinant G-CSF protein, 4T1 or AT-3 tumor cells (tumor volumes approximately
1000 mm
3) (as in Fig. 1). Values shown in the upper right quadrant of each dot plot reveal the percentage of the CD11b
+Gr-1
+ myeloid fraction. Data
are representative of 3 separate experiments for each group. (B) CD11b
+ cells in panel A were gated and then re-plotted for expression of the Ly6G
and Ly6C markers to determine the proportion of granulocytic (upper right) and monocytic (upper left) MDSC subsets within each group. Data are
representative of 3 separate experiments for each group. (C) Ability of CD11b
+Gr-1
+ isolated from control (PBS) or G-CSF-treated mice to suppress
anti-CD3 mAb-stimulated CD3
+ T cells (1610
5/well) at the indicated cell densities. CD11b
+Gr-1
+ cells from G-CSF, but not vehicle (PBS)-treated mice
significantly suppressed T cell proliferation compared to the control (i.e., no CD11b
+Gr-1
+ cells added; *P,0.01). (D)A si nC, CD11b
+Gr-1
+ cells from G-
CSF-treated or AT-3 tumor-bearing mice significantly (*P,0.02) suppressed allo-specific (H-2
b anti-H-2
d) T cell proliferation compared to control
without CD11b
+Gr-1
+ cells. Responders (1610
5/well) and stimulators (2610
5/well) from unfractionated splenocytes were incubated together with or
without isolated CD11b
+Gr-1
+ cells from the indicated mice (1610
5/well). In both C & D, proliferation was measured by
3H-thymidine uptake (mean 6
SEM) of triplicate determinations and are representative of two separate experiments.
doi:10.1371/journal.pone.0027690.g002
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We found that sera G-CSF levels were significantly lower in mice
b e a r i n gA T - 3s h R N A1t u m o rc e l l sc o m p a r e dt ot h ec o n t r o l( F i g .S 3
panel B). Thus, altering tumor-derived G-CSF levels exerted a
significant impact on tumor growth.
Down-regulation of Tumor-derived G-CSF Reduces MDSC
Burden
To determine whether differences in tumor-derived G-CSF levels
also affected granulocytic MDSC accumulation, we analyzed
splenic MDSC frequencies from both groups of mice with equal
tumor volumes of 800 – 1000 mm
3 (i.e., collected from the control
group on day 52 vs shRNA 1 group on day 73). First, we observed
significant reductions in splenocyte numbers in mice bearing AT-3
shRNA 1 tumor cells compared to the control (Fig. 5A). Second, to
determine whether these splenic differences reflected differences in
MDSC populations, we analyzed unfractionated splenocytes for co-
expression of the CD11b and Gr-1 markers (Fig. 5B). AT-3 shRNA
1 tumor-bearingmicedisplayed a greaterthan two-fold reductionin
the percentage of CD11b
+Gr-1
+ cells compared to the control
Figure 3. Gene expression analysis of CD11b
+Gr-1
high myeloid cells from G-CSF-treated mice reveal remarkable similarities with
those of 4T1 tumor-bearing mice. (A) Genome-wide mRNA microarray studies were conducted on purified splenic CD11b
+Gr-1
high cells isolated
from three groups of BALB/c mice: non-tumor-bearing control (WT), G-CSF treated (GCSF) or 4T1 tumor-bearing (TB) mice. The number of genes
differentially expressed ($2-fold change; P,0.01) for each of the indicated comparisons is shown in bar plot. There were 932, 734 and 22 genes
showing significant expression change in 4T1-TB vs. WT, GCSF vs. WT, and 4T1-TB vs. G-CSF respectively. The fraction of genes up- or down-regulated
are shown in gray or black, respectively. (B) Hierarchical clustering of differentially expressed ($2-fold change; P,0.01) genes from comparisons for
4T1-TB vs. WT, G-CSF vs. WT, and 4T1-TB vs. G-CSF respectively. The color scale of heat map represents the relative expression level of a gene (i.e., red,
increased; green, decreased) across the samples.
doi:10.1371/journal.pone.0027690.g003
Figure 4. G-CSF blockade slows tumor growth. (A) B6 mice were implanted with AT-3 tumor cells, followed 10 days later with treatment with a
neutralizing anti-G-CSF mAb or a rat isotype control (10 mg daily for 8 consecutive days). Treatment of mice with anti-G-CSF mAb significantly
(*P,0.05) reduced AT-3 tumor growth at the indicated time points (from days 20-30). Data expressed as the mean 6 SEM of 4 mice/group. (B) AT-3
cells were transduced with a scrambled shRNA sequence (non-silencing control) or different G-CSF specific shRNA sequences (constructs 1–3).
Individual stable cell lines were propagated in vitro and analyzed for G-CSF expression, along with parental AT-3 cells, by RT-PCR for the indicated
genes. (C) Cell-free supernatants from G-CSF knockdown vs. non-silencing control cell lines were analyzed for secreted protein by ELISA (P,0001). (D)
To evaluate the effect of G-CSF knockdown on tumor growth, AT-3 control and AT-3 shRNA-1 cells were implanted into separate groups of B6 mice
and monitored for tumor growth (n=5 mice each). G-CSF knockdown led to a significant delay (*P,0.03) in tumor growth at several time points
indicated (from days 38 – 59). Data in panels C&Dare reported as mean 6 SEM and are representative of 3 separate experiments.
doi:10.1371/journal.pone.0027690.g004
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MDSC subset(s) were affected most, we analyzed these preparations
for granulocytic and monocytic fractions based on differential
expression of the Ly6C and Ly6G epitopes in the gated CD11b
+
fraction (Fig. 5C). Importantly, we found significant reductions in
the percentage (Fig. S3 panel C) and number (Fig. 5C) of
granulocytic MDSC from mice bearing AT-3 shRNA 1 tumor
cells compared to the control. Conversely, the monocytic fraction
remained largely unaffected, indicating a preferential effect on the
granulocytic subset.
Fourth, to determine whether MDSC were affected qualita-
tively, splenic CD11b
+Gr-1
+ cells were isolated and tested for their
ability to inhibit allo-specific T cell proliferation (Fig. 5D). MDSC
derived from both AT-3 shRNA 1 and control tumor-bearing
mice, however, displayed comparable capacity to suppress allo-
specific T cell proliferation. These data indicated that G-CSF
knockdown in AT-3 tumors can slow tumor growth and reduce
granulocytic MDSC burden; however, the suppressive capacity of
CD11b
+Gr-1
+ MDSC was not altered. Thus, tumor-derived G-
CSF likely plays a more dominant role in affecting the quantity of
granulocytic MDSC, which still translates to a significant effect on
primary tumor growth.
Over-expression of Tumor-Derived G-CSF Production
Augments Tumor Growth
To further demonstrate causality between tumor-derived G-
CSF with tumor growth and MDSC accumulation, we made use
of a gain-of-function approach. As shown earlier, CMS4 sarcoma
cells secrete undetectable levels of G-CSF protein (Fig. 1B).
Therefore, CMS4 cells were stably transfected with a murine G-
CSF expression plasmid or an empty vector control. Both G-CSF-
producing CMS4 cells and parental AT-3 tumor cells displayed
high levels of G-CSF mRNA, whereas G-CSF transcript was
undetectable in the CMS4 vector control cells (Fig. 6A).
Differences in G-CSF expression were confirmed at the protein
level (Fig. 6B).
In a reciprocal fashion to our G-CSF loss-of-function approach
(Figs. 4 and 5), we explored the impact of G-CSF gain-of-function
Figure 5. G-CSF knockdown reduces MDSC accumulation. (A) Splenocyte numbers were quantified from B6 mice with equivalent tumor
burdens (800 – 1000 mm
3) of vector control and shRNA-1 AT-3 cells. Splenocyte numbers were significantly higher (*P,0.004) in the control
compared to the G-CSF knockdown cohort (n=5 mice each). (B) Flow cytometric analysis of unfractionated splenocytes in panel A revealed a
dramatic decrease in the percentage of CD11b
+Gr-1
+ cells in the control compared to the G-CSF knockdown cohort (n=5 mice each). (C) Splenocytes
in panel B were evaluated for granulocytic and monocytic MDSC subsets based on additional staining with anti-Ly6G and Ly6C mAb. Absolute
numbers of the MDSC subsets were then calculated using splenocyte data in panel A. G-CSF knockdown led to a significant decrease (*P,0.02) in the
granulocytic fraction (n=3 mice each). (D) CD11b
+Gr-1
+ cells isolated from mice in panel A were assayed for their ability to suppress T cell
proliferation in a one-way MLR (1 of 2 separate experiments) (*P,0.02 compared to the control).
doi:10.1371/journal.pone.0027690.g005
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CMS4 tumors expressing G-CSF grew significantly faster than the
vector control tumor cells (Fig. 6C). For reference, we observed
that 10/10 mice bearing G-CSF-producing CMS4 cells displayed
tumor volumes .500 mm
3, whereas none of the control cells
achieved that level at these time points. Again, this G-CSF effect
was not due to intrinsic differences in tumor cell growth in vitro,a s
proliferation was comparable between both cell lines (Fig. S4 panel
A). Moreover, this effect did not reflect an autocrine loop, as both
groups of CMS4 tumor cells did not express the G-CSF receptor
(Fig. S4 panel B). To verify that differences in tumor growth
correlated with differences in G-CSF levels, sera from both groups
of mice with equal tumor volumes were analyzed for G-CSF
protein. We observed that sera G-CSF levels were significantly
higher in mice bearing G-CSF-producing CMS4 cells compared
to the control cells (Fig. S4 panel C). Thus, modulation of tumor-
derived G-CSF levels exerts a significant impact on tumor growth.
Over-expression of Tumor-Derived G-CSF Increases
Granulocytic MDSC Burden
Mice implanted with G-CSF-producing CMS4 cells, compared
to the control, exhibited a massive increase in spleen size and
splenocyte number (Fig. 7A and Fig. S4 panel D). Such analyses
were performed on mice with equivalent tumor burdens of
,1000 mm
3. It is important to note that the control tumors
required a longer time to achieve this tumor volume (i.e., 2
additional weeks). Mice bearing G-CSF-producing CMS4 cells
also had an approximately 7-fold higher percentage of
CD11b
+Gr-1
+ cells compared to those implanted with the control
cells (Fig. 7B; 48.7% to 7.2%). Moreover, myeloid subset analysis
revealed significant increases in the percentage (Fig. S4 panel E)
and number (Fig. 7C) of granulocytic cells in mice bearing the G-
CSF-producing tumor compared to the control tumor. It is also
interesting to note that the number of monocytic cells also
increased, although not to the same extent (Fig. 7C).
To determine whether tumor-derived G-CSF also affected
function, we examined the ability of CD11b
+Gr-1
+ cells from
control and G-CSF-producing tumor-bearing mice to inhibit allo-
specific T cell proliferation. As with the AT-3 model (Fig. 5D),
CD11b
+Gr-1
+ cells derived from both groups of tumor-bearing
mice suppressed T cell proliferation at significant and comparable
levels (Fig. 7D). These data indicate that MDSC are generated in
this CMS4 model, and that tumor-derived G-CSF likely plays a
greater role in the development and accumulation of these cells
compared to affecting their suppressive behavior.
Granulocytic MDSC Enhances Tumor Growth
Thus far, our data demonstrate that tumor-derived G-CSF
impacts tumor growth, as well as granulocytic MDSC accumu-
lation. However, it remained to be determined whether the effect
Figure 6. G-CSF over-expression enhances tumor growth in vivo. (A) RT-PCR analysis for G-CSF or GAPDH mRNA levels performed on parental
AT-3 cells or stably transfected CMS4 cells expressing murine G-CSF or the vector control (VC). (B) Cell-free supernatants from CMS4 cells of panel A
were quantified for G-CSF levels by ELISA. Data are reported as the mean 6 SEM (pg/ml/10
6 cells/24 hr) of 4 separate experiments (*P,0.0001). (C)
BALB/c mice were implanted with either G-CSF-producing CMS4 cells or the vector control (4610
5/mouse) and monitored for tumor growth. In all
mice, G-CSF-expressing tumors grew significantly faster than the vector control (n=10 mice each).
doi:10.1371/journal.pone.0027690.g006
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mechanism. To do so, we adopted two approaches; one was based
on a direct assessment of the functional impact of the MDSC
subset in the tumor microenvironment, and the second was based
on cell depletion (Fig. 8).
Phenotypic characterization of the primary tumor microenvi-
ronment, in this case the 4T1 model, revealed a substantial
infiltration of CD11b
+Gr-1
+ cells with the vast majority bearing a
granulocytic phenotype (Fig. 8A and B). Thus, it is clear that
granulocytic MDSC can infiltrate or traffic to the tumor
microenvironment. To determine whether such cells are also
functional at the tumor site, we took advantage an ‘admix’
approach to directly assess the impact of the myeloid population
on tumor growth originally described by Moses and colleagues
[40,41]. The granulocytic fraction was purified from G-CSF-
treated mice by flow cytometric sorting of splenic CD11b
+ cells co-
expressing high levels of Gr-1, as in Fig. 3. Such cells were mixed
with 4T1 tumor cells and then implanted into new groups of
syngeneic mice. We observed that CD11b
+Gr-1
high cells from G-
CSF-treated mice significantly enhanced tumor growth compared
to 4T1 cells injected alone (Fig. 8C). Earlier studies in this 4T1
model showed that CD11b
+Gr-1
+ cells from non-tumor-bearing
mice are not pro-tumorigenic and do not alter tumor growth,
compared to tumor cells injected alone [38]. In contrast,
CD11b
+Gr-1
+ cells from 4T1 tumor-bearing mice enhanced
tumor growth, compared to tumor cells injected alone or tumor
cells admixed with myeloid counterparts from the non-tumor-
bearing controls [38].
Our second approach was based on Gr-1 cell depletion, widely
used in the tumor field [34,42,43]. Although targeting the Gr-1
populations is not necessarily MDSC-specific, it has been used as a
‘proof-of-concept’ approach to assess the potential role of Gr-1-
expressing cells [34,42,43] in affecting a disease outcome. Besides
Gr-1 cell depletion as a loss-of-function approach, to our
knowledge no other alternative has been reported that can
specifically deplete or inactivate MDSC without potentially
impacting the tumor or host compartments. We hypothesized
that if G-CSF enhances tumor growth through mobilization of
Figure 7. G-CSF over-expression enhances MDSC accumulation. (A) Splenocyte numbers were quantified from BALB/c mice with equivalent
tumor burdens (,1000 mm
3) of vector control and G-CSF-producing CMS4 cells. This experiment is separate from that shown in Fig. 5. Splenocyte
counts were significantly higher (*P,0.0002) from mice bearing the G-CSF-producing tumor cells compared to the vector control (n=5 mice each).
(B) Flow cytometric analysis of unfractionated splenocytes in panel A revealed a dramatic increase in the percentage of CD11b
+Gr-1
+ cells (upper right
quadrant) in mice bearing the G-CSF-producing CMS4 cells compared to the vector control. (C) Splenocytes in panel B were evaluated for
granulocytic and monocytic MDSC subsets based on additional staining with Ly6G and Ly6C mAb. Absolute numbers of the MDSC subsets were then
calculated using splenocyte data in panel A. G-CSF over-expression resulted in a significant increase (*P,0.0001) in both subsets, although a more
pronounced effect in terms of numbers was seen in the granulocytic subset (n=3 mice each). (D) CD11b
+Gr-1
+ cells isolated from mice in panel A
were assayed for their ability to suppress T cell proliferation in a one-way MLR (1 of 2 experiments) (*P,0.02 compared to the control).
doi:10.1371/journal.pone.0027690.g007
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+Gr-1
hi cells from G-CSF-treated mice are pro-tumorigenic. Tumor tissue was recovered from individual 4T1 tumor-bearing
BALB/c mice, enzymatically digested and then analyzed by flow cytometry for the percentages of the global MDSC response (panel A), as well as the
granulocytic and monocytic MDSC subsets (panel B) as in Fig. 2. The enzyme cocktail contained DNase I (30 U/ml), collagenase A (1 mg/ml) and
hyaluronidase (0.1 mg/ml, Sigma). Data are representative of 4 separate mice, and the differences between both granulocytic and monocytic MDSC
subsets were significant (*P,0.003). Compilation of data points in panels A and B are shown on the right side of each dot plot. (C) CD11b
+Gr-1
+ cells
were isolated from the spleens of G-CSF-treated BALB/c mice (see Fig. 2 for treatment) by two-color flow cytometric sorting. The sort focused on the
recovery of CD11b
+Gr-1
high cells, consistent with the granulocytic fraction. 4T1 tumor cells (5610
4/mouse) were then injected alone or admixed with
these CD11b
+Gr-1
high cells (2.5610
4/mouse) just prior to orthotopic tumor challenge (2:1 ratio of tumor:myeloid population). Tumor growth data
expressed as the mean 6 SEM of 4 mice/group. * Indicates significant P-values,0.05 between the two groups at the indicated time points. (D) Vector
control or G-CSF expressing CMS4 cells were implanted into BALB/c mice, as in Fig. 6. When tumors became palpable, all mice were treated with anti-
Gr-1 mAb or rat IgG control. Data are reported as mean 6 SEM of 5 mice per group (P,0.04 for the various comparisons at day 20).
doi:10.1371/journal.pone.0027690.g008
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expressing myeloid cells would result in a reduction of tumor
growth. To avert a leukopenia-induced moribund state due to
repeated injections of the antibody, however, the experiment was
carried out until differences in tumor growth were observed
between groups. To that end, we returned to our CMS4 model in
which G-CSF levels are regulated experimentally.
Treatment of mice bearing the G-CSF-expressing tumor with
anti-Gr-1 mAb reduced tumor growth, which approached levels
seen with the vector control tumor (Fig. 8D) (P,0.04 for the
various comparisons at day 20). The reduction in tumor growth
became more apparent over time, consistent with a time-
dependent component for anti-Gr-1 mAb treatment to build up
to a biologic effect. In contrast, anti-Gr-l mAb treatment had no
effect on the growth of the vector control tumor compared to
treatment with the isotype control (Fig. 8D). These data are
consistent with the undetectable levels of tumor-derived G-CSF
and low MDSC burden in the parental CMS4 model, and
reinforces the likelihood that anti-Gr-1 mAb treatment did not
exert non-specific effects against tumor growth. Overall, these data
reveal that tumor-derived G-CSF potentiates tumor growth via
granulocytic MDSC, thus unveiling a previously undescribed ‘G-
CSF-granulocytic MDSC-tumor axis’ in regulating tumor pro-
gression.
Discussion
MDSC are a major regulatory myeloid population that
accumulates during a range of pathologic processes and function
to inhibit innate and adaptive immunity [1,2,3,4,5,6,7,8]. MDSC
can be found systemically in the blood and peripheral lymphoid
tissues, as well as locally at sites of disease activity. It turns out that
granulocytic cells comprise a major component of the MDSC
response [1,17,18,19,20,21]; albeit, the underlying reasons for this
remain unclear. Therefore, efforts to understand how they develop
will have valuable implications for the design of new therapeutic
paradigms. Although a number of other TDF have been linked to
diverse elements of MDSC biology, namely VEGF, GM-CSF, IL-
1b, IL-6, PGE2, IFN-c, SCF or IL-17 [1,3,5,15,44], none have
been rigorously tested to explain the connection between
granulocytic MDSC response and tumor growth. Given that the
granulocytic MDSC response is a likely manifestation of
deregulated granulopoiesis, we hypothesized that inappropriate
production of tumor-derived G-CSF contributes to granulocytic
MDSC accumulation. Similarly, other groups have found positive
correlations between G-CSF production and aberrant granulo-
cytic or MDSC-like responses in several mouse models [32,33,34].
However, despite the correlation, the causal basis for granulocytic
MDSC accumulation remained untested.
Three systematic in vivo approaches were taken to validate the
role of G-CSF in granulocytic MDSC generation: 1) loss-of-
function using RNA interference; 2) gain-of-function using a
tumor model over-expressing G-CSF protein; and 3) direct
injection of purified G-CSF protein. Using multiple approaches,
our data support the hypothesis that tumor-derived G-CSF
facilitates granulocytic MDSC generation which displays both
immunosuppressive and pro-tumorigenic activities. Furthermore,
G-CSF protein alone was sufficient to generate granulocytic-like
MDSC, which strongly recapitulated phenotypic, functional and
molecular characteristics observed with tumor-induced granulo-
cytic MDSC. These data imply that high concentrations of G-CSF
acting in a systemic and aphysiologic manner can impair normal
myeloid cell development or differentiation, leading to the
accumulation of granulocytic-like MDSC. Thus, exogenous or
endogenous stores of G-CSF may have paradoxical roles during
certain pathologic circumstances, including neoplasia.
Our data do not necessarily preclude the potential role of host-
derived G-CSF. However, the loss- and gain-of-function studies
directly implicate a prominent role of tumor-derived G-CSF in the
accumulation of granulocytic MDSC. The possibility that a ‘G-
CSF-granulocytic MDSC-tumor axis’ may be important in a
broader sense is supported by our data in multiple tumor models
or approaches, and the fact that G-CSF production has been
identified in several human cancer types [26,27,28,29,30,31]. It is
important to note that these data do not exclude the possibility
that other TDF play relevant roles in granulocytic MDSC biology,
especially in the absence of G-CSF production or in a G-CSF-
independent manner. For example, in cases where tumors produce
high amounts of GM-CSF, the monocytic fraction tends to
accumulate more so than the granulocytic fraction, although the
latter subset is still represented [13,14].
In addition to its affects on granulocytic MDSC burden, we
observed that tumor-derived G-CSF affects tumor growth rate.
Through G-CSF blockade, as well as G-CSF loss- and gain-of-
function approaches, we found that altering G-CSF levels had a
direct impact on tumor growth. To directly demonstrate that
granulocytic MDSC are pro-tumorigenic activity, highly purified
CD11b
+Gr-1
high cells from G-CSF-treated mice were collected,
admixed with 4T1 cells and implanted orthotopically into naı ¨ve
recipients. We found that such myeloid-tumor admixtures
significantly enhanced tumor growth, demonstrating that granu-
locytic-like populations induced by G-CSF treatment are pro-
tumorigenic within the tumor microenvironment. Moreover,
depleting Gr-1
+ cells in mice bearing G-CSF-producing, but not
non-G-CSF-producing tumors facilitated a significant reduction in
tumor growth, supporting a causal link between G-CSF-induced
granulocytic MDSC accumulation and tumor progression.
Our data also implicate an important effect of G-CSF on the
monocytic MDSC subset. Indeed, modulation of tumor G-CSF
levels was accompanied by quantitative changes in the monocytic
fraction, albeit, not to the same magnitude. Moreover, our data
indicate that the monocytic fraction from tumor-bearing mice
expressed appreciable levels of the G-CSF receptor (Fig. S5).
Although it remains undetermined whether G-CSF affects the
monocytic fraction directly or indirectly, this latter observation
suggests that G-CSF may do so in part through a direct
mechanism. Thus, the impact of tumor-derived G-CSF may have
broader consequences on the overall MDSC response. Finally, it
remains to be determined what regulates constitutive tumor-
derived G-CSF production in the first place. As this study
necessarily focused on the mechanistic basis of a ‘G-CSF-
granulocytic MDSC-tumor axis’, we believe these new data now
provide the framework for pursuing in detail how G-CSF is
regulated by neoplastic cells.
Taken collectively, we demonstrated: 1) a novel role of G-CSF
in myeloid biology, acting at the level of granulocytic MDSC
accumulation; 2) that granulocytic MDSC can facilitate tumor
growth, indicating a previously unrecognized causal link between
this MDSC subset and neoplastic progression; 3) that recombinant
G-CSF administration alone to healthy mice can promote
granulocytic MDSC development, which may help to explain in
part the basis of certain immune-associated adverse events in
healthy individuals that receive G-CSF injections to mobilize
progenitor cells for use in hematopoietic transplant settings [24];
and 4) that experimental approaches that target the initiating TDF
(i.e., G-CSF) leads to tumor growth inhibition under conditions of
host immunosurveillance. Current MDSC-based pharmacologic
approaches include vitamin D3, retinoic acid (ATRA), KIT-
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ref. 1). Thus, therapeutic targeting of TDF that initiate
granulocytic MDSC development may offer additional ways to
abrogate MDSC-mediated mechanisms of tumor growth, thereby
enhancing immunotherapy efficacy.
Materials and Methods
Mice
All experiments were conducted and approved under our
Institutional Animal Care and Use Committee (IACUC) at
Roswell Park Cancer Institute under protocol ID numbers
1108 M and 1117 M and in accordance with institutional
regulations, NIH and Public Health Service policies. Female
C57BL/6 (B6) or BALB/c (6 – 8 wks of age) mice were obtained
from the NCI-Frederick Cancer Research Animal Facility
(Frederick, MD). The MMTV-PyMT/B6 transgenic mouse,
termed MTAG, expresses the polyomavirus middle T antigen
controlled through the MMTV-LTR promoter [39], originally
derived in FVB mice, was backcrossed .10 times onto a C57BL/6
(H-2
b) background and kindly provided by S. Gendler (Mayo
Clinic, Scottsdale, AZ). MTAG mice develop multifocal mamma-
ry carcinomas.
Tumor cell lines
The 4T1 mammary tumor cell line (ATCC, Manassas, VA) was
derived from BALB/c mice [37] and maintained in a RPMI-based
medium [38]. The AT-3 tumor cell line was established from a
primary mammary gland carcinoma of a MTAG mouse [45] and
propagated in a DMEM-based medium. The CMS4 sarcoma line,
a kind gift of A. DeLeo (Univ. of Pittsburgh, Pittsburgh, PA), was
derived from BALB/c mice and maintained in a RPMI-based
medium. In vitro assays were performed in a RPMI-based medium.
In vivo tumor growth and G-CSF studies
Female BALB/c mice were injected orthotopically in an
abdominal mammary gland with 5610
4 4T1 cells. Female B6
mice were injected similarly with 5610
5 AT-3 cells, including
those cell lines used in the knockdown studies. For the G-CSF
over-expression tumor studies, syngeneic BALB/c mice were
injected subcutaneously into the flank with 4610
5 CMS4 cells. In
the admix experiments, 5610
4 4T1 tumor cells were mixed with
MACS-purified, MHC-matched CD11b
+Gr-1
+ cells at a 2:1 ratio,
respectively, prior to orthotopic implantation. Spleens, serum and
tumor tissue were recovered, as appropriate. For the G-CSF
blockade studies, B6 mice were injected orthotopically, and on day
7 when tumors became palpable, mice were injected intraperito-
neally with 10 mg of either neutralizing anti-G-CSF mAb or rat
IgG isotype (R&D Systems) for 8-consecutive days, as described
[36]. For the in vivo depletion experiments, BALB/c mice were
injected ip with anti-Gr-1 Ab (clone RB6-8C5; BioXcell, West
Lebanon, NH) or control Ab (Rat IgG2b clone LTF-2; BioXcell,
West Lebanon, NH). Antibodies were administered at 200 mg/
mouse once tumors became palpable, and continued twice weekly
for the duration of the experiment, similarly as described
[38,42,43]. For all tumor experiments, mice were euthanized
when tumor volumes approached 2 cm
3 or for other health
considerations. Tumor growth was measured 2 – 3 times/week in
two dimensions and tumor volume was calculated using the
formula (width
26length)/2. For recombinant G-CSF in vivo
studies, mice were injected subcutaneously with recombinant G-
CSF (10 mg/day, Peprotech, Rocky Hill, NJ) for 5 consecutive
days and serum/tissues collected, similarly as described [46].
Isolation of mouse CD11b
+Gr-1
+ cells
Splenic CD11b
+Gr-1
+ cells were purified from the indicated
groups using similarly established protocols [16,38,47,48]. Selec-
tions were performed using CD11b
+ magnetic beads from
Miltenyi Biotec (Auburn, CA) on an AutoMACs system. The
percentage of CD11b
+ cells was routinely .95%. Of these cells,
.90% co-expressed CD11b and Gr-1 markers in both control and
tumor-bearing mice, as previously reported [38].
Flow cytometry
Myeloid preparations were pre-incubated with anti-CD16/32
mAb (BD Biosciences, San Diego, CA) to block Fc receptor
binding, followed by incubation with directly conjugated primary
mAb, as described [38]. Labeled cells were collected on a
FACSCalibur flow cytometer (BD, San Jose, CA) and analyzed
by FCS-Express software (De Novo Software, Los Angeles, CA).
Antibodies reactive against the following cell surface markers were
used (including appropriate isotype controls): CD11b (BioLegend,
San Diego, CA), Ly6G, Ly6C, Gr-1 (BD Biosciences) and G-CSF
receptor mAb (Abcam, Cambridge, MA).
Immune suppression assays
Flat-bottomed, 96-well plates were coated with anti-CD3 mAb
(1 mg/well) (BD Biosciences). Total splenic T cells were purified
from naı ¨ve mice using the AutoMACS system, and plated at
5610
4 cells/well. Isolated CD11b
+Gr-1
+ cells were added to the
plate at multiple CD11b
+Gr-1
+ cell:T cell ratios. Plates were
incubated for 48 hr at 37uC, after which
3H-thymidine (1 mCi/
well) was added for an additional 24 hr. Proliferation determined
by measuring
3H-thymidine uptake [38]. For the mixed
lymphocyte reaction (MLR), one-way allogeneic H-2
b anti-H-2
d
or H-2
d anti-H-2
b cultures was established. Responders (1610
5
unfractionated splenocytes/well from naı ¨ve mice) were cultured
with irradiated (20 Gy) stimulators (2610
5 unfractionated
splenocytes, also from naı ¨ve mice) in 96-well, U-bottomed plates.
MHC-matched CD11b
+Gr-1
+ splenocytes were then added to the
allo-assay at one or more cell densities. Plates were incubated for
96 hr at 37uC, after which
3H-thymidine was added for an
additional 24 hr, and cells harvested as above.
Fluorescence-activated cell sorting (FACS)
To efficiently isolate CD11b
+ Gr-1
high myeloid cells from WT
control, 4T1 tumor-bearing and recombinant G-CSF treated
mice, we first incubated total splenocytes with CD11b (BioLegend,
San Diego, CA) and Gr-1 (BD Biosciences) antibodies as indicated
previously. 4T1 tumor-bearing mice had tumor burdens of
.1000 mm
3, whereas mice treated with recombinant G-CSF
were given a dose regimen as previously indicated. The cells were
sorted on a FACSAria cell sorter (BD Biosciences) and analyzed
using FACSDiva software (BD Biosciences). The FACS resulted in
.98% recovery of the CD11b
+ Gr-1
high population. Total RNA
was extracted from 5610
6 sorted cells using Qiagen’s miRNeasy
kit, which was quantified and subsequently used for microarray
analysis.
G-CSF under-expression and over-expression studies
RNA interference methods were used to silence G-CSF
expression in AT-3 tumor cells. Stably, transduced cell lines were
generated by the shRNA core facility at Roswell Park. Briefly, the
retroviral vector, pSM2, was engineered to contain several
independent sequences targeting murine G-CSF expression
(henceforth termed, shRNA 1 (71191), 2 (68539), 3 (64790) or
non-silencing/scrambled control) (Open Biosystems/Thermo
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transduced with the individual G-CSF shRNA-containing retro-
viral supernatants. Cells were stably propagated under puromycin
selection (2 mg/ml). For the G-CSF over-expression studies,
murine G-CSF cDNA was PCR-cloned from AT-3 cells using
the following primers: forward: 59-AAAAAACACCATGGCT-
CAACTTTCTGCCC-39; reverse: (59-AAAAAGCGGCCGCC-
TAGGCCAAGTGGTGCAGA-39. Afterwards, the gene was gel-
purified, inserted into the pcDNA3.1(+) expression plasmid
(Invitrogen, Carlsbad, CA), amplified, and purified under
endotoxin-free conditons for use in transfection. CMS4 cells were
then transfected with the expression vector or empty vector as a
control using Lipofectamine (Invitrogen) per manufacturer’s
instructions. Cells were stably propagated under G418 (800 mg/
ml) selection.
Cytokine analysis
Cell-free supernatants from tumor cell lines (1610
6 cells/ml)
were collected after incubation for 24 hr at 37uC. Serum was also
collected, and all samples were stored at 280uC until assayed.
Comprehensive analysis of cytokines was initially performed using
Quansys multipex ELISA services (Quansys Biosciences, Logan,
UT). Subsequently, G-CSF levels were quantified using G-CSF-
specific ELISA (R&D Systems, Minneapolis, MN).
RT-PCR analyses
Total RNA was isolated using RNeasy Mini kits (Qiagen;
Valencia, CA) according to manufacturer’s instructions. cDNA
was synthesized using the ThermoScript RT-PCR system
(Invitrogen). The cDNA was then used as the template for PCR
amplification of the indicated murine genes in a PTC-200 thermal
cycler (MJ Research, Waltham, MA) under the following standard
conditions: 94uC for 2 min, 30 cycles (94uC for 30 sec, 60uC for
30 sec and 72uC for 1 min) and 72uC for 10 min. The following
mouse primer sets were used: G-CSF forward: 59-CTCA-
ACTTTCTGCCCAGAGG-39 and reverse: 59-AGCTGGCT-
TAGGCACTGTGT-39; PyMT (MTAG) forward: 59-AGTCA-
CTGCTACTGCACCCAG-39 and reverse: 59-CTCTCCTCAG-
TTCCTCGCTCC-39; VEGF-A forward: 59-CTGTGCAGGC-
TGCTGTAACG-39 and reverse: 59-GTTCCCGAAACCCTG-
AGGAG-39; VEGF-C forward: 59-TGTGGGGAAGGAGTT-
TGGAGC-39 and reverse: 59-CGGCAGGAAGTGTGATTG-
GC-39; COX-2 forward: 59-ACAACATCCCCCTCCTGCG-39
and reverse: 59-GCTCCTTATTTCCCTTCACACCC-39, GAP-
DH forward: 59-CATCACCATCTTCCAGGAGCG-39 and re-
verse: 59-ACGGACACATTGGGGGTAGG -39. PCR products
were separated on a 1% agarose gel and the images captured with
the Chemidoc Imaging System (BioRad, Hercules, CA).
Microarray analysis
Total RNA from highly purified splenic CD11b
+Gr-1
high cells
from the different experimental groups was quantified by a ND-
1000 spectrophotometer (NanoDrop, Thermo Scientific) and
evaluated for degradation using a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). Samples requirements were as
follows: RIN .7, an OD 260:280 of 1.9-2.0, and an OD 260/230
.1.8. The MouseWG-6 whole-genome gene expression array and
direct hybridization assay was used for expression profiling
(Illumina Inc., San Diego, CA). Initially, we converted 250–
500 ng total RNA to cDNA, followed by in vitro transcription to
generate biotin-labeled cRNA (Illumina TotalPrep RNA Ampli-
fication Kit, Ambion Inc., Austin, TX). 750 ng of the labeled
probes were then mixed with hybridization reagents and
hybridized overnight at 58uC to the MouseWG-6 v2 BeadChips.
Following washing and staining with Cy3-streptavidin conjugate,
the BeadChips were imaged using the Illumina iScan Reader to
measure fluorescence intensity of each probe, where intensity
corresponds to the quantity of the respective mRNA in the original
sample. The expression profiles have been deposited in NCBI’s
Gene Expression Omnibus (GEO) with GSE accession number
GSE32209. All data is MIAME compliant.
BeadChip data files were then analyzed with Illumina’s
GenomeStudio gene expression module and R-based Bioconduc-
tor package to determine gene expression signal levels [49].
Briefly, the raw intensity of Illumina MouseWG-6 gene expression
array was scanned and extracted using BeadScan, with the data
corrected by background subtraction in GenomeStudio module.
The lumi module in the R-based Bioconductor Package was used to
transform the expression intensity into log2 scale [50]. The log2
transformed intensity data were normalized using Quantile
normalization function. We then performed three separate
comparisons for 4T1-TB versus WT, G-CSF versus WT and
4T1-TB versus G-CSF. We used the Limma program in the R-
based Bioconductor package to calculate the level of gene differential
expression for each comparison [51]. Briefly, a linear model was fit
to the data (with cell means corresponding to the different
condition and a random effect for array), and selected contrast for
each comparison was performed. For each comparison, we
obtained the list of differentially expressed genes ($2-fold change)
constrained by P,0.01. Results are reported from data collected
on two biologic replicates of each group.
Statistical analysis
For comparisons between control and experimental groups,
data were recorded as mean 6 SEM of the indicated number of
mice or experiments. Statistical analysis was determined using a
two-sided unpaired t-test or exact Wilcoxon Rank Sum tests,
where appropriate. P-values less than 0.05 were considered
significant.
Supporting Information
Figure S1 High levels of G-CSF produced by DA-3 and
EMT-6 mammary carcinomas. Cell-free supernatants from
DA-3 or EMT-6 mammary carcinoma cell lines were collected
and analyzed by ELISA for G-CSF secretion (pg/ml/10
6 cells/
24 hr). DA-3 cells produced high levels of G-CSF
(33,00063605 pg/ml); EMT-6 cells also produced an appreciable
level of G-CSF (1,6876120 pg/ml). Data expressed as the mean
6 SEM of triplicate determinations.
(TIF)
Figure S2 Recombinant G-CSF administration results
in a selective increase in CD11b
+ Gr-1
+ myeloid cells. (A)
BALB/c mice were treated with recombinant mouse G-CSF
protein (10 mg/day for 8 consecutive days). Two days following the
last injection, spleens were collected. Splenocytes from untreated
or G-CSF-treated mice were analyzed by flow cytometry for the
indicated cell surface marker. CD11b
+Gr-1
+ cells were strongly
increased following G-CSF treatment, which was accompanied by
a corresponding reduction in other major lymphoid populations.
Data represent the mean percentage positive cells 6 SEM (n=5
mice/group). (B) Small aliquots of the indicated CD11b
+Ly6-
C
highLy6G
- and CD11b
+Ly6C
low Ly6G
+ cells in Fig. 2 were
collected by cell sorting, and then evaluated morphologically by a
hematopathologist to verify monocytic and granulocytic cell types.
Photomicrographs were taken of representative areas under 40X
magnification.
(TIF)
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growth in vitro, serum G-CSF levels and MDSC fre-
quences in vivo. (A) Control and shRNA 1 AT-3 cells were
measured for potential differences in proliferation in vitro by the
MTS assay, a variation of the MTT assay. Tumor cell lines were
incubated in flat-bottomed, 96-well plate for 24 hr at multiple cell
densities. After incubation time, the MTS solution was added and
the extent of proliferation was determined by measuring OD at
490 nm. (B) Stability of G-CSF knockdown in vivo was determined
by measuring systemic G-CSF levels from both groups of mice
with comparable tumor volumes (800 – 1000 mm
3). Data
expressed as the mean 6 SEM (n=3; P,0.02). (C) Splenocytes
were isolated from mice bearing control and shRNA 1 AT-3 cells
at comparable tumor volumes, and analyzed for the percentages of
granulocytic and monocytic subsets. G-CSF knockdown in AT-3
cells led to a significant decline in granulocytic MDSC. Data
expressed as the mean positive staining 6 SEM (n=3; P,0.02).
(TIF)
Figure S4 Impact of G-CSF over-expression on tumor
growth in vitro, serum G-CSF levels and MDSC fre-
quences in vivo. (A) CMS4-vector control (CMS4-VC) and G-
CSF-producing CMS4 cells (CMS4-GCSF) were measured for
potential differences in proliferation in vitro as in Fig. S3. Data
expressed as the mean OD (at 490 nm) 6 SEM (n=3). (B) Each
cell line was also analyzed for G-CSF receptor expression by flow
cytometry. One of 3 representative experiments is shown. (C)
Stability of G-CSF over-expression in vivo was determined by
measuring systemic G-CSF levels from the two groups of mice
with equivalent tumor volumes (,1000 mm
3). Data expressed as
the mean 6 SEM (n=5; P,0.0001). (D) Photograph of
representative spleens from CMS4-VC or CMS4-GCSF tumor
bearing mice (,1000 mm
3). (E) Splenocytes in D were isolated
from mice bearing CMS4-VC or CMS4-G tumors, and analyzed
by flow cytometry for the percentages of granulocytic and
monocytic subsets, based on differential staining with anti-
CD11b, Ly6C and Ly6G mAb. G-CSF over-expressing CMS4
tumors showed a significant rise in granulocytic MDSC, with a
corresponding drop in monocytic MDSC relative to the control.
Data expressed as the mean positive staining 6 SEM (n=5;
P,0.0004).
(TIF)
Figure S5 G-CSF receptor expression on monocytic and
granulocytic MDSC. G-CSF receptor expression was analyzed
on splenic MDSC subsets from the indicated CMS4 tumor-
bearing mice. Splenocytes were stained for CD11b and Gr-1
expression and then further gated based on differential Gr-1 levels
(Gr-1
high or Gr-1
low) to phenotypically distinguish granulocytic
from monocytic MDSC subsets, respectively. The gated cells were
then analyzed for G-CSF receptor expression relative to isotype
control staining.
(TIF)
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